40 - hupo - home · 2016-09-06 · pieter jelle visser, alzheimer centre, vu university medical...
TRANSCRIPT
![Page 1: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/1.jpg)
![Page 2: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/2.jpg)
40 speakers35% with PhD after 2008
42% female and 58% male
60 participants
11 countriesAustralia, Brazil, Canada, Germany, Ireland, Korea,
Luxemburg, Netherlands, Spain, Sweden, USA
2 local organizers
1 company
![Page 3: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/3.jpg)
Eating, socializing and networking
![Page 4: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/4.jpg)
Young Mok Park &
Helmut Meyer
Mathias Uhlen at the HBPP pub
![Page 6: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/6.jpg)
coming HBPP Workshops26th: HUPO Taipei Sep 19, 201627th: Bochum, Germany, May 9‐10 201728th: HUPO Dublin Sep 201729th: May 2018, HUPO west or east region30th: HUPO Orlando Sep 2018
Presentations will be available for participants
A report will be written for Proteomics
Thank you all who contributed to make this a very succesful event!!
![Page 7: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/7.jpg)
25th HUPO Human Brain Proteome Project Workshop, Stockholm May 3‐4, 2016Final agenda
WelcomePeter Nilsson, KTH ‐ Royal Institute of Technology, Stockholm, SwedenAnna Häggmark, KTH ‐ Royal Institute of Technology, Stockholm, Sweden
HBPP historyHelmut E Meyer, ISAS ‐ Leibniz‐Institut für Analytische Wissenschaften, Dortmund, GermanyYoung Mok Park, Center for Cognition and Sociality, Institute for Basic Science, Daejeon, Korea
Session 1: Tissue‐based proteomic profilingChair: Jan Mulder
Addressing the challenges of quantitative myelin proteomicsOlaf Jahn, Proteomics Group, Max‐Planck‐Institute of Experimental Medicine, Göttingen, Germany
Brainstem: a promising target for new discoveries in neurodegenerative diseasesRenata Leite, Physiopathology in Aging Lab and Discipline of Geriatrics, University of Sao Paulo Medical School, Brazil
Antibody based profiling of protein distribution in the brain, focus on normal physiology and diseaseJan Mulder, Science for Life Laboratory, Department of Neuroscience, Karolinska Institutet, Stockholm , Sweden
How to explore brain proteins in the normal tissue atlasEvelina Sjöstedt, SciLifeLab, KTH, Stockholm, Sweden and Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
Atlas Antibodies: Advanced research reagents for studying human proteinsEugenia Kuteeva, Atlas Antibodies AB
Session 2: Technical advancements in neuroproteomicsChair: Oliver Schubert
Revealing proteomics of cerebral organoids from human pluripotent stem cells: aiming to understand the mechanisms of brain diseasesJuliana Minardi Nascimento, Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, University of Campinas, Sao Paulo, Brazil
MRM as proteomic tool for the analysis of cerebrospinal fluid in neurodegenerative diseasesPatrick Oeckl ,Department of Neurology, Ulm University Hospital, Ulm, Germany
Brain up your analysis methodology ‐ Proteome Bioinformatics and Biostatistics in Clinical ResearchMartin Eisenacher, Medizinisches Proteom‐Center, Ruhr‐University Bochum, Bochum, Germany
Diagnostic and therapeutic potential of extracellular vesicles
![Page 8: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/8.jpg)
Fouzi El Magraoui, Biomedical Research , Human Brain Proteomics, Leibniz‐Institut für Analytische Wissenschaften –ISAS e.V., Dortmund, Germany
Clinical proteomics and peptidomics for identification of cerebrospinal fluid biomarkers of neurodegenerative disordersJohan Gobom, Institute of Neuroscience and Physiology, Section of Psychiatry and Neurochemistry, University of Gothenburg
Antibody‐based CSF profiling within multiple sclerosis reveals disease‐asociated profiles of GAP43 and SERPINA3Anna Häggmark, Affinity Proteomics, Scilifelab, KTH ‐ Royal Institute of Technology, Stockholm, Sweden (presented by Peter Nilsson)
Effects of hypertension on the brain: an initial top‐down proteomic analysis.Jens R. Coorssen, School of Medicine, Nanoscale Organisation & Dynamics Group, School of Science & Health, Western Sydney University, Australia
Quantifying DementiaJudith Steen, Harvard Medical School, Boston Children’s Hospital, F.M. Kirby Center for Neurobiology, Boston, USA
Session 3: Psychiatric disordersChair: Daniel Martins‐de‐Souza
Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical responseDaniel Martins‐de‐Souza, Laboratory of Neuroproteomics, Dept of Biochemistry, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil
Peripheral blood gene expression and proteomic analysis implicates B‐cell development and ribosomal proteins in cognitive dysfunction in people with remitted Major DepressionK. Oliver Schubert, Discipline of Psychiatry, School of Medicine, University of Adelaide, Australia
Proteomic approaches to understanding the postsynaptic density in schizophrenia and bipolar disorderDavid Cotter, Royal College of Surgeons in Ireland, Dublin, Ireland
Investigating protein pathology in schizophrenia by identifying the insoluble proteomeCarsten Korth, Institut für Neuropathologie, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany
Proteome‐wide study of cerebrospinal fluid biomarkers for bipolar disorder ‐ multiplexed semi‐quantification by mass spectrometryJessica Holmén Larsson ,Institute of Neuroscience and Physiology, Sahlgrenska Academy at Goteborg University, Mölndal, Sweden
Advancing Biomarker Discovery in Age 12 Children with Psychotic Disorder: Results from the ALSPAC CohortJane A English, Department of Psychiatry, Royal College of Surgeons in Ireland, Dublin, Ireland
Uppsala Psychiatric Patient Samples ‐ UPPJanet Cunningham, Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden
Gene expression alterations of complement factors in schizophreniaEva Lindholm Carlström, Uppsala University, Uppsala, Sweden
![Page 9: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/9.jpg)
Pub and mingle An update on the Human Protein AtlasMathias Uhlen, SciLifeLab, KTH ‐ Royal Institute of Technology, Stockholm, Sweden
Session 4: Alzheimer's diseaseChair: Helmut E Meyer
Biomarker for early AD diagnostics Helmut E Meyer, Leibniz‐Institut für Analytische Wissenschaften –ISAS e.V., Dortmund, Germany
Brain enriched proteins in CSF – GAP43 and friendsJulia Remnestål, Affinity Proteomics, Scilifelab, KTH ‐ Royal Institute of Technology, Stockholm, Sweden
Characteriza on of the Abeta and Neurogranin pep de pa erns – from blood to the brainErik Portelius, Institute of Neuroscience and Physiology, Sahlgrenska Academy at Goteborg University, Mölndal, Sweden
Molecular endophenotypes in Alzheimer’s diseasePieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen)
Proteomics in Alzheimer’s diseaseKim Kultima, Department of Medical Sciences, CARAMBA, Cancer Pharmacology and Computational Medicine, Uppsala University, Uppsala, Sweden
Thinking outside of the brain in Alzheimer's disease using proteomics technologyRenã A. S. Robinson, Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Session 5: PD and other dementiasChair: Katrin Marcus
Analysis of cerebrospinal fluid using high resolution mass spectrometryKatrin Marcus, Medizinisches Proteom‐Center, Ruhr‐University Bochum, Bochum, Germany
Robust metabolic biomarkers for Parkinson's diseaseKarsten Hiller, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg
RTP801/REDD1 interactome in a cellular model of PDCristina Malagelada Grau, Unit of Biochemistry, Department of Biomedicine, University of Barcelona, Barcelona, Spain
Proteomics Profiling of the Substantia Nigra Reveals Association of RNA Metabolism Pathways and Arp2/3‐Mediated Actin Nucleation with Lewy Body PresenceVladislav Petyuk, Pacific Northwest National Laboratory, Richland, USA
![Page 10: 40 - HUPO - Home · 2016-09-06 · Pieter Jelle Visser, Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands (presented by Charlotte Teunissen) Proteomics in](https://reader033.vdocuments.us/reader033/viewer/2022042709/5f51f4760a9e1f4b327a1730/html5/thumbnails/10.jpg)
Identification of CSF biomarkers for specific dementia’s by Mass spectrometry proteomicsCharlotte Teunissen, VU University Medical Center Amsterdam – department of Clinical Chemistry, Amsterdam, Netherlands
Integrated Biomarker Discovery in Parkinsonian DisordersMiles Trupp, Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden
Session 6: Autoimmunity in brain disordersChair: Peter Nilsson
Anoctamin 2 as a novel autoimmune target in multiple sclerosisPeter Nilsson, Affinity Proteomics, Scilifelab, KTH ‐ Royal Institute of Technology, Stockholm, Sweden
New insights into brain disordersCaroline May, Medizinisches Proteom‐Center, Ruhr‐Universität Bochum, Bochum, Germany
High‐density Antibody and Phage Microarray screening of prefrontal cortex brain tissue and sera of Alzheimer Disease Patients for the identification of specific AD markers
Rodrigo Barderas, Functional Proteomics of Chronic Diseases, Biochemistry and Molecular Biology Department, Complutense University of Madrid, Spain
Profiling autoantibody repertoires within psychiatric disordersDavid Just, Affinity Proteomics, Scilifelab, KTH ‐ Royal Institute of Technology, Stockholm, Sweden
Session 7: Other neurological disordersChair: Charlotte Teunissen
Somalogic‐based proteomics to identify and validate biomarkers in blood of Multiple SclerosisArjan Malekzadeh, VU University Medical Center Amsterdam, Netherlands (presented by Charlotte Teunissen)
Vascular biomarkers in ALS neurodegenerationSebastian Lewandowski, Vascular Biology Group, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
Multiplexed MRM Quantitation of Candidate Protein Biomarkers in Human CSFChristoph Borchers, University of Victoria ‐ Genome British Columbia Proteomics Centre, Victoria, BC, Canada
Proteomics in multiple sclerosisClaire Bridel, VU University Medical Center Amsterdam, Netherlands